Investigation of the metabolic features of primary glioblastomas by Tc-MIBI SPECT/CT and evaluation of their effect on disease prognosis

Zolotova S.V.; Khokhlova E.V.; Belyashova A.S.; Nikolaeva A.A.; Starovoytov D.V.; Igoshina E.N.; Barinov A.A.; Absaliamova O.V.; Banov S.M.; Golanov A.V.

doi:https://doi.org/10.17116/neiro20198302117

Zolotova S.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

Khokhlova E.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

Belyashova A.S.

Burdenko Neurosurgical Institute, Moscow, Russia

Nikolaeva A.A.

Burdenko Neurosurgical Institute, Moscow, Russia

Starovoytov D.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Igoshina E.N.

Burdenko Neurosurgical Institute, Moscow, Russia

Barinov A.A.

Burdenko Neurosurgical Institute, Moscow, Russia

Absaliamova O.V.

FGBU "Nauchno-issledovatel'skiĭ institut neĭrokhirurgii im. akad. N.N. Burdenko"

Banov S.M.

Gamma Knife Center, Moscow, Russia

Golanov A.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

ORCID: 0000-0002-0976-4547

Investigation of the metabolic features of primary glioblastomas by Tc-MIBI SPECT/CT and evaluation of their effect on disease prognosis

Authors:

Zolotova S.V., Khokhlova E.V., Belyashova A.S., Nikolaeva A.A., Starovoytov D.V., Igoshina E.N., Barinov A.A., Absaliamova O.V., Banov S.M., Golanov A.V.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2019;83(2): 17‑26

DOI: 10.17116/neiro20198302117

Read: 2284 times

To cite this article:

Zolotova SV, Khokhlova EV, Belyashova AS, et al. . Investigation of the metabolic features of primary glioblastomas by Tc-MIBI SPECT/CT and evaluation of their effect on disease prognosis. Burdenko's Journal of Neurosurgery. 2019;83(2):17‑26. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20198302117

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118

TERTp mutation screening using digital droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95

Problems of pregnancy planning and gestation in patients with diffuse toxic goiter after radiotherapy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):82-87

The choice of radiotherapy dose fractionation regimen for grade 4 gliomas depending on the status of MGMT. P.A. Herzen Journal of Oncology. 2025;(1):13-18

Radiation therapy with focal dose escalation in the treatment of glioblastoma. P.A. Herzen Journal of Oncology. 2025;(2):64-69

Radical cystectomy with fertility preservation for non-muscle invasive bladder cancer. P.A. Herzen Journal of Oncology. 2025;(2):76-82

Prognostic significance and comparison of methods for calculating tumor budding in gastric cancer. Russian Journal of Archive of Pathology. 2025;(3):17-25

Lean management example at the radiotherapy department. Medical Technologies. Assessment and Choice. 2025;(2):67-73

Prevention and treatment of dermal toxicity in children receiving anti-tumor radiation. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):470-480

Proton therapy of skull base chordoma. P.A. Herzen Journal of Oncology. 2025;(5):64-67

Abstract:

Objective — to study the effect of metabolic characteristics of the tumor determined by 99mTc-MIBI single-photon emission computed tomography (SPECT) and various molecular genetic features on the outcomes of combination treatment of hemispheric glioblastomas. Materials and methods. This single-center prospective cohort study involved 68 patients aged 25—78 years (38 males and 30 females) with primary glioblastomas. Hypermetylation of the promotor region of the MGMT gene was observed in 24 (42%) out of 57 patients. The IDH1 mutation was revealed in two (3.5%) patients. The catamnestic data were available for 66 out of 68 patients. The first SPECT/CT study was carried out before chemoradiation therapy; the second SPECT/CT study was performed after the chemoradiation therapy. In each study, quantitative measures were calculated for the early (15—30 min after the patient had received a radiopharmaceutical) and late (after 45—60 min) phases. Results. The actuarial survival rates after 12 and 24 months were 69.6 and 29.1%, respectively. The median overall survival rate was 17.5 months (95% CI 12.9—20.3). Favorable prognostic factors for overall survival included the higher uptake index (UI) in the late phase compared to UI in the early phase of the first SPECT/CT study (p=0.0444), dynamics of changes in UI during the second SPECT/CT compared to baseline over 10% (p=0.0436), MGMT hypermethylation (p=0.0003), and duration of the period between surgery and initiation of chemoradiotherapy being <1 month (p=0.0008). No statistically significant correlations were revealed between the absolute UI values in the tumor and its molecular genetic features. Conclusion. The 99mTc-MIBI SPECT/CT can be used to predict overall survival and to plan radiation therapy of glioblastoma as it is more readily available at primary healthcare facilities than amino acid PET.

Keywords:

glioblastoma

99mTc-MIBI SPECT/CT

metabolic activity

radiotherapy

survival rate

Authors:

Zolotova S.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

Khokhlova E.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

Belyashova A.S.

Burdenko Neurosurgical Institute, Moscow, Russia

Nikolaeva A.A.

Burdenko Neurosurgical Institute, Moscow, Russia

Starovoytov D.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Igoshina E.N.

Burdenko Neurosurgical Institute, Moscow, Russia

Barinov A.A.

Burdenko Neurosurgical Institute, Moscow, Russia

Absaliamova O.V.

FGBU "Nauchno-issledovatel'skiĭ institut neĭrokhirurgii im. akad. N.N. Burdenko"

Banov S.M.

Gamma Knife Center, Moscow, Russia

Golanov A.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

ORCID: 0000-0002-0976-4547

Close metadata

References:

Louis DN, Perry A, Reifenberger G, Deimling A von, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica. 2016;131:6:803820. https://doi.org/10.1007/s00401-016-1545-1
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011—2015. Neuro-Oncology. 2018.20(suppl 4):iv1-iv86. https://doi.org/10.1093/neuonc/noy131
Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. Journal of neuro-oncology. 2012;107:1:207-212. https://doi.org/10.1007/s11060-011-0738-7
Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015;33:25:2735-2744. https://doi.org/10.1200/JCO.2015.61.5005
Stupp R, Mason WP, van den Bent, Martin J, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005;352:10:987-996. https://doi.org/10.1056/NEJMoa043330
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England journal of medicine. 2014; 370:8:709-722. https://doi.org/10.1056/NEJMoa1308345
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England journal of medicine. 2014;370:8:699-708. https://doi.org/10.1056/NEJMoa1308573
Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, N.Y.). 2008;321:5897: 1807-1812. https://doi.org/10.1126/science.1164382
Louis DN, et al. WHO classification of tumours of the central nervous system. 4-e izd. Lyon: International Agency For Research On Cancer, 2016;408 Seiten.
Lobanova NV, Shishkina LV, Ryzhova MV, Kobyakov GL, Sycheva RV, Burov SA, Lukyanov AV, Omarova ZR. Klinicheskie, immunogistologiheskie i molekulyarno-geneticheskie prognosticheskie faktory u vsroslykh patients s glioblastomoy. Arkhiv patologii. 2016;78:4:10-19. https://doi.org/10.17116/patol201678410-19
McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer. 2003;98:8: 1745-1748. https://doi.org/10.1002/cncr.11666
Sarmiento JM, Mukherjee D, Black KL, Fan X, Hu JL, Nuno MA, Patil CG. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations? Journal of neurological surgery. Part A. Central European neurosurgery. 2003;77:3:195-200. https://doi.org/10.1055/s-0035-1566121
Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, Sakai N. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. Journal of neurology, neurosurgery, and psychiatry. 2004;75:10:1457-1462. https://doi.org/10.1136/jnnp.2003.028480
Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller H-W, Zilles K, Coenen HH, Langen K-J. O-(2-18Ffluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain: a journal of neurology. 2005;128:Pt 3:678-687. https://doi.org/10.1093/brain/awh399
Bolcaen J, Acou M, Boterberg T, Vanhove C, Vos F de, van den Broecke C, van Holen R, Deblaere K, Goethals I. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria. Nuclear medicine communications. 2017;38:3:242-249. https://doi.org/10.1097/MNM.0000000000000638
Calabria F, Cascini GL. Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence. Hellenic journal of nuclear medicine. 2015;18:2:152-156. https://doi.org/10.1967/s0024499100211
Cheng X, Li Y, Xu Z, Li D, Wang J. A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2011;18:3:307-312. https://doi.org/10.1016/j.jocn.2010.07.113
Tan CHA, Tan EHA. Post-treatment Assessment of Glioblastoma Multiforme: Imaging with Fluorodeoxyglucose, Sestamibi, and Choline. World journal of nuclear medicine. 2012;11:1:30-32. https://doi.org/10.4103/1450-1147.98745
Booth TC, Tang Y, Waldman AD, Quigley A.-M, Lewis D, Soloviev D, Nathan M, Bhogal P, Jefferies S, Buscombe JR. Neuro-Oncology Single-Photon Emission CT: A Current Overview. Neurographics. 2011;1:3:108-120. https://doi.org/10.3174/ng.3110014
Stupp R, Brada M, van den Bent, MJ, Tonn J-C, Pentheroudakis G. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2014;25(Suppl 3):iii93-iii101. https://doi.org/10.1093/annonc/mdu050
Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, Hentati D, Guedes de Castro D, Dyttus-Cebulok K, Drodge S, Ghosh S, Jeremić B, Rosenblatt E, Fidarova E. International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33:35:4145-4150. https://doi.org/10.1200/JCO.2015.62.6606
Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2017; 14:2:307-320. https://doi.org/10.1007/s13311-016-0507-6
Moretti J-L, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. European Journal of Nuclear Medicine and Molecular Imaging. 2005;32:7:836-842. https://doi.org/10.1007/s00259-005-1840-x
Kinuya S, Yokoyama K, Li X-F, Bai J, Watanabe N, Shuke N, Takayama T, Bunko H, Michigishi T, Tonami N. Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with (99m)Tc-sestamibi, (201)Tl chloride and (99m)Tc-HL91. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29:8:1006-1011. https://doi.org/10.1007/s00259-002-0846-x
Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31:32: 4085-4091. https://doi.org/10.1200/JCO.2013.49.6968
Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29:34:4482-4490. https://doi.org/10.1200/JCO.2010.33.8715
Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre J-Y. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27:25:4150-4154. https://doi.org/10.1200/JCO.2009.21.9832
Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, Li G, Li S, Wu C, Yao K, Li W, Yan W, Li J, You Y, Chen CC, Jiang T. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget. 2015;6:38:40896-40906. https://doi.org/10.18632/oncotarget.5683
Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, Wiemels JL, Nelson HH, Karagas MR, Wrensch MR, Kelsey KT, Wiencke JK. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. Journal of the National Cancer Institute. 2011;103:2:143-153. https://doi.org/10.1093/jnci/djq497
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent, Martin J, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28:11:1963-1972. https://doi.org/10.1200/JCO.2009.26.3541
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent, Martin J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. The Lancet Oncology. 2008;9:5:453-461. https://doi.org/10.1016/S1470-2045(08)70125-6
Yoo R-E, Choi SH. Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients. Magnetic resonance in medical sciences. MRMS: an official journal of Japan Society of Magnetic Resonance in Medicine. 2016;15:2:165-177. https://doi.org/10.2463/mrms.rev.2015-0053